Oral delivery of Trichinella spiralis antigens by yeast-derived β-glucan particles enhances anti-helminth immunity Authors: Zhina Liu, Yi Liu, Zijian Dong, Yaming Yang, Longjiang Tian, Xingyang Wang, Zhiyang Du, Xiaolei Liu, Xue Bai, Xuemin Jin Published: 2026 ABSTRACT Intestinal helminth infections including Trichinella spiralis impose a heavy burden globally, yet effective oral vaccines are lacking due to antigen degradation and poor mucosal immunogenicity. This study develops an oral vaccine platform using yeast-derived β-glucan particles (GPs) to encapsulate T. spiralis antigens (Ag-GPs). These Ag-GPs demonstrated efficient antigen encapsulation, gastrointestinal stability, and excellent biocompatibility. In a mouse model, oral immunization with Ag-GPs was biocompatible and induced robust mucosal (SIgA) and systemic (IgG, IgE) antibody responses, while also stimulating dendritic cell maturation and T-cell activation. This immunization resulted in significant reductions in both adult worm and muscle larval burdens following T. spiralis challenge. Notably, the observed protective immunity strongly correlated with Dectin-1 receptor-mediated particle uptake and subsequent systemic immune activation. This work presents a promising dual-function platform, acting as both an adjuvant and delivery system, for developing oral vaccines against intestinal parasites. Introduction Intestinal helminth parasites, which have co-evolved with their hosts over millennia, continue to pose significant health challenges worldwide1. Approximately one billion people worldwide are infected with intestinal helminths, a burden that notably affects human health, especially in developing regions2. Parasites such as Trichinella spiralis not only affect livestock health but also have significant economic consequences, with intestinal helminth infections estimated to cost Europe €1.8 billion annually3. Despite variations in life cycles and pathogenic effects among intestinal parasites, the intestine invariably represents the first line of defense against their infection4,5. Over recent decades, a number of vaccine strategies have been explored to control T. spiralis infection, primarily focusing on reducing muscle larval burdens6. However, few vaccine studies have successfully targeted the intestinal mucosa to elicit robust immune responses against T. spiralis. Effective vaccines against intestinal helminths should ideally inhibit larval development within the gut and facilitate the rapid clearance of adult worms. The success of such vaccines relies heavily on the choice of potent adjuvants and an optimal delivery route7. One major challenge is that protein-based antigens exhibit low oral bioavailability, leading to the induction of strong protective mucosal immune responses8–10. An ideal oral vaccine carrier system is therefore expected to protect antigens from degradation and provide intrinsic adjuvant activity. β‑glucans, derived from yeast, mushrooms, fungi, and grains, are known for their potent immunomodulatory effects11,12. We previously demonstrated that oral β‑glucans substantially reduced the T. spiralis burden in mice13. GPs, directly extracted from baker’s yeast, are rough, porous, hollow spheres capable of encapsulating protein antigens and other compounds14–16. These particles are remarkably resistant to gastrointestinal degradation, making them promising carriers for intestinal antigen delivery17,18. Upon oral administration, stable GPs traverse the gastrointestinal tract and target intestinal immune cells effectively. Given their particle size, GPs are hypothesized to be transported by Microfold cells (M cells) into Peyer’s patches (PP), where they can target intestinal antigen-presenting cells. GPs effectively target intestinal antigen-presenting cells and stimulate both mucosal and systemic immune responses by internalizing via the Dectin‑1 receptor, leading to antigen processing (innate immunity) and activation of T and B cell responses (adaptive immunity)19–21. Therefore, β‑glucan particles offer a promising platform for effective mucosal vaccines against T. spiralis. To our knowledge, this study is the first to employ a GPs-based oral vaccine platform in the field of parasitic infections, exploiting these particles’ unique properties to protect and deliver parasitic antigens while enhancing mucosal immunity. This strategy overcomes critical challenges, such as antigen degradation and poor bioavailability by taking advantage of the intrinsic immunomodulatory properties of β‑glucans. More broadly, our findings support further development of oral vaccines targeting intestinal helminths, which may contribute to better control of these infections. Results Efficient Ag encapsulation in GPs: structural analysis GPs were prepared from yeast using acid-base extraction to remove intracellular components and cell wall proteins. The resulting GPs can absorb soluble antigens through capillary action during a simple mixing process (Fig. 1A). Morphological characterization of yeast, GPs, and Ag-GPs was performed using SEM and TEM. SEM analysis revealed that GPs exhibited a hollow interior structure following chemical treatment (Fig. 1B), confirming the removal of cytoplasmic contents. TEM imaging revealed porous structure on GPs (Fig. 1C), which can serve as channels for Ag loading. Following the Ag-loading process, TEM images of Ag-GPs displayed enhanced internal contrast compared to unloaded GPs, with flocculent substances observed within the pore channels (Fig. 1D), suggesting potential Ag encapsulation. Particles size analysis via ImageJ software demonstrated uniform Ag-GPs dimensions (3.27 ± 0.38 µm), with no significant differences in size or surface morphology between GPs and Ag-GPs (Fig. 1B, D). It is speculated that Ag predominantly localizes within the interstices of GPs. The zeta potential values of Ag-GPs (−3.90 ± 0.06 mV) was higher than those of yeast (−25.30 ± 2.65 mV) and GPs (−10.36 ± 0.33 mV), corresponding to previous reports on ovalbumin-loaded GPs22 (Fig. 1E).Fig. 1Preparation and characterization of Ag-GPs.A The Ag-GPs vaccine is prepared by synthesizing GPs through the acid-base and organic solvent washing method, followed by encapsulating Ag into the GPs via capillary action. B SEM morphological characterization of yeast, GPs, and Ag-GPs. C Ultrastructural analysis of yeast, GPs, and Ag-GPs by TEM. D The size of yeast, GPs and Ag-GPs. All bars represent mean ± SD (n = 40). E The zeta potential of yeast, GPs and Ag-GPs. All bars represent mean ± SD (n = 3). F FTIR spectra of Ag, neat GPs, and GPs/Ag. G Confocal microscopy images showing the incorporation of RB-labeled Ag (red) into CFW-labeled GPs (blue) to form Ag-GPs. H The retention rate of Ag in Ag-GPs at different incubation times under pH buffer conditions (pH = 1.2, 6.8). Data are presented as mean ± SD (n = 3). **P < 0.01, ****P < 0.0001. Preparation and characterization of Ag-GPs. A The Ag-GPs vaccine is prepared by synthesizing GPs through the acid-base and organic solvent washing method, followed by encapsulating Ag into the GPs via capillary action. B SEM morphological characterization of yeast, GPs, and Ag-GPs. C Ultrastructural analysis of yeast, GPs, and Ag-GPs by TEM. D The size of yeast, GPs and Ag-GPs. All bars represent mean ± SD (n = 40). E The zeta potential of yeast, GPs and Ag-GPs. All bars represent mean ± SD (n = 3). F FTIR spectra of Ag, neat GPs, and GPs/Ag. G Confocal microscopy images showing the incorporation of RB-labeled Ag (red) into CFW-labeled GPs (blue) to form Ag-GPs. H The retention rate of Ag in Ag-GPs at different incubation times under pH buffer conditions (pH = 1.2, 6.8). Data are presented as mean ± SD (n = 3). **P < 0.01, ****P < 0.0001. FTIR confirmed the successful incorporation of Ag, as Ag-GPs exhibited two characteristic peaks originating from Ag at 1540 cm⁻¹ and 1658 cm⁻¹ (Fig. 1F). Furthermore, CLSM confirmed Ag localization within CFW-GPs, showing uniform RB-Ag fluorescence in the core (Fig. 1G). At a GPs/Ag mass ratio of 5, GPs achieved an encapsulation efficiency of 72.30 ± 2.17% and loading efficiency of 12.65 ± 0.33%. The stability of Ag-GPs in simulated gastrointestinal conditions The stability of Ag-GPs in the gastrointestinal tract was evaluated by incubation in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF). CLSM images of the incubated Ag-GPs revealed no fragmentation, with particle shapes and sizes remaining unchanged (Fig. S1a, b). Microscopic counting at various time points showed no significant changes in the number of retained Ag-GPs (Fig. S1c). These data demonstrate that GPs maintained structural stability, ensuring subsequent recognition by immune cells. To avoid enzymatic interference with zeta potential and Ag release, PBS buffers (pH 1.2 and 6.8) replaced SGF and SIF. Zeta potential of Ag-GPs demonstrated pH-dependent trends: values of 1.97 ± 0.22 mV (1 h) and 2.13 ± 0.33 mV (2 h) at pH 1.2, and −5.78 ± 0.77 mV (4 h), -5.26 ± 0.27 mV (6 h), and -5.40 ± 0.10 mV (8 h) at pH 6.8 (Fig. S1d). Additionally, Ag release from Ag-GPs was quantified. At the reaction endpoint, 49.40% of the initial Ag was retained within GPs (Fig. 1H). Biocompatibility and safety evaluation of Ag-GPs A hemolysis test was conducted to investigate the effect of Ag-GPs on sheep red blood cells. The results showed that the hemolysis remained below 0.01 within the designated concentration range (Fig. 2A), indicating excellent blood compatibility of Ag-GPs. Additionally, co-culture experiments with Ag-GPs demonstrated that the cell survival rate was above 85% even at a high concentration, indicating that Ag-GPs did not exhibit cytotoxicity towards these cells (Fig. 2B).Fig. 2Safety evaluation of Ag-GPs.A The hemolytic potential of various concentrations (6.25–200 μg/mL) of Ag-GPs. ddH2O (100% lysis) and PBS (0% lysis) were used as positive and negative controls, respectively. Data are presented as mean ± SD (n = 3). B Cytotoxicity of Ag-GPs at different concentrations on Raw264.7, DC2.4 and Caco-2 cells. Data are presented as mean ± SD (n = 3). C–F Liver and kidney function markers in immunized mice. Serum biochemistry analysis showing levels of albumin (ALB), alanine aminotransferase (ALT), blood urea nitrogen (BUN), and (d) creatinine (CRE). All bars represent mean ± SD (n = 3). Safety evaluation of Ag-GPs. A The hemolytic potential of various concentrations (6.25–200 μg/mL) of Ag-GPs. ddH2O (100% lysis) and PBS (0% lysis) were used as positive and negative controls, respectively. Data are presented as mean ± SD (n = 3). B Cytotoxicity of Ag-GPs at different concentrations on Raw264.7, DC2.4 and Caco-2 cells. Data are presented as mean ± SD (n = 3). C–F Liver and kidney function markers in immunized mice. Serum biochemistry analysis showing levels of albumin (ALB), alanine aminotransferase (ALT), blood urea nitrogen (BUN), and (d) creatinine (CRE). All bars represent mean ± SD (n = 3). Hematological and biochemical analyses showed that blood cell counts and hemoglobin levels were within the normal range (Table S1). Histological examination of tissue and organs using H&E staining revealed normal cellular structures with no significant pathological changes (Fig. S2). Liver and kidney function markers (ALB, ALT, BUN, CRE) showed no significant differences compared to the control group (Fig. 2C–F). Ag-GPs uptake by phagocytic cells and promotion of BMDC maturation CLSM images showed that RB-Ag-GPs (Fig. S3a) were efficiently internalized by phagocytic cells (Raw264.7 and DC2.4). Notably, no uptake in Caco-2 cells (Fig. 3A). Furthermore, ex vivo imaging revealed strong fluorescence signals in the PP, the inguinal lymph nodes (ILN), mesenteric lymph nodes (MLN) of mice given with FITC-Ag-GPs (Fig. S3b), compared to PBS-treated controls (Fig. 3B). These results showed that Ag-GPs can absorbed by intestine, then recognized and transported to lymphoid organs by phagocytic cells.Fig. 3Ag-GPs is internalized by phagocytic cells and stimulate the maturation of BMDCs.A CLSM images showing RB-Ag-GPs (red) internalized by PKH67-stained (green) Raw264.7, DC2.4, and Caco-2 cells with DAPI-labeled nuclei (blue) after incubation. B Ex vivo fluorescence imaging of BALB/c mice orally administered PBS or FITC-Ag-GPs, showing biodistribution in secondary lymphoid tissues (ILN, PP, MLN), IE, and major organs (heart, liver, spleen, lung, kidney, small intestine), with fluorescence intensity indicating Ag-GPs uptake. C–F Flow cytometry analysis of BMDCs activation. C Single-cell gating; D CD11c⁺ DC identification; E CD86⁺CD80⁺ double-positive cell selection; F Quantification of activated DCs after treatment with PBS, Ag, GPs, or Ag-GPs. Data are presented as mean ± SD (n = 3), ****P < 0.0001. Ag-GPs is internalized by phagocytic cells and stimulate the maturation of BMDCs. A CLSM images showing RB-Ag-GPs (red) internalized by PKH67-stained (green) Raw264.7, DC2.4, and Caco-2 cells with DAPI-labeled nuclei (blue) after incubation. B Ex vivo fluorescence imaging of BALB/c mice orally administered PBS or FITC-Ag-GPs, showing biodistribution in secondary lymphoid tissues (ILN, PP, MLN), IE, and major organs (heart, liver, spleen, lung, kidney, small intestine), with fluorescence intensity indicating Ag-GPs uptake. C–F Flow cytometry analysis of BMDCs activation. C Single-cell gating; D CD11c⁺ DC identification; E CD86⁺CD80⁺ double-positive cell selection; F Quantification of activated DCs after treatment with PBS, Ag, GPs, or Ag-GPs. Data are presented as mean ± SD (n = 3), ****P < 0.0001. The immunomodulatory effects of Ag-GPs on BMDCs were analyzed by flow cytometry. Mice immunized with GPs and Ag-GPs showed a marked expansion of CD11c⁺CD86⁺CD80⁺ BMDCs versus PBS and Ag-treated controls (P < 0.0001; Fig. 3F). This indicates Ag-GPs enhance BMDC maturation. Ag-GPs enhance T cell differentiation and lymphocyte proliferation The Ag-GPs group exhibited a significant increase in CD3⁺ T-cell counts compared to other groups (P < 0.05, P < 0.01, and P < 0.0001; Fig. 4C), accompanied by a marked elevation in CD4⁺ T-cell proportions (P < 0.01, P < 0.001; Fig. 4D). In contrast, the Ag-GPs group showed reduced CD8⁺ T-cell proportions relative to PBS controls (P < 0.05; Fig. 4E), leading to a significantly higher CD4⁺/CD8⁺ ratio (P < 0.05, P < 0.01; Fig. 4F), indicative of robust immune activation.Fig. 4Flow cytometric analysis of splenic lymphocytes immune responses in vaccinated mice.A Identification of CD3⁺ T cells from splenocytes using APC-conjugated anti-CD3 antibody. B Subsequent classification of CD4⁺ (FITC⁺) and CD8⁺ (PE⁺) T cell subsets within the CD3⁺ population. C Quantitative analysis of CD3⁺ T cell frequency among total splenocytes. Data are presented as mean ± SD (n = 3), *P < 0.05, **P < 0.01, ****P < 0.0001. D Proportion of CD4⁺ T cells within CD3⁺ population. Data are presented as mean ± SD (n = 3), **P < 0.01, ***P < 0.001. E Proportion of CD8⁺ T cells within CD3⁺ population. Data are presented as mean ± SD (n = 3), *P < 0.05. F CD4⁺/CD8⁺ T cell ratio. Data are presented as mean ± SD (n = 3), *P < 0.05, **P < 0.01. G Ag-specific lymphocyte proliferation measured by ex vivo splenocyte stimulation assay. Data are presented as mean ± SD (n = 3), ***P < 0.001 and ****P < 0.0001. Flow cytometric analysis of splenic lymphocytes immune responses in vaccinated mice. A Identification of CD3⁺ T cells from splenocytes using APC-conjugated anti-CD3 antibody. B Subsequent classification of CD4⁺ (FITC⁺) and CD8⁺ (PE⁺) T cell subsets within the CD3⁺ population. C Quantitative analysis of CD3⁺ T cell frequency among total splenocytes. Data are presented as mean ± SD (n = 3), *P < 0.05, **P < 0.01, ****P < 0.0001. D Proportion of CD4⁺ T cells within CD3⁺ population. Data are presented as mean ± SD (n = 3), **P < 0.01, ***P < 0.001. E Proportion of CD8⁺ T cells within CD3⁺ population. Data are presented as mean ± SD (n = 3), *P < 0.05. F CD4⁺/CD8⁺ T cell ratio. Data are presented as mean ± SD (n = 3), *P < 0.05, **P < 0.01. G Ag-specific lymphocyte proliferation measured by ex vivo splenocyte stimulation assay. Data are presented as mean ± SD (n = 3), ***P < 0.001 and ****P < 0.0001. To assess Ag-GPs’ ability to boost adaptive immunity, we conducted in vitro proliferation assays on spleen lymphocytes stimulated with Ag. The Ag-GPs group exhibited significantly enhanced lymphocyte proliferation compared to the Ag group (P < 0.001, P < 0.0001; Fig. 4G). These results indicate that Ag-GPs promote the processing and presentation of Ag, enhance adaptive immunity. Ag-GPs elicit robust humoral immunity and protective efficacy We further evaluated antibody responses against T. spiralis. Ag-GPs group showed higher antibody titers than other groups in Ag-specific IgG levels at various time points (P < 0.05, P < 0.01, P < 0.001, P < 0.0001, Fig. 5B). Similar changes were observed in Ag-specific IgE (P < 0.01, P < 0.001, P < 0.0001, Fig. 5C) and Ag-specific SIgA (P < 0.05, P < 0.01, P < 0.0001, Fig. 5D). These results show that Ag-GPs immunization enhances both mucosal SIgA and systemic immune responses.Fig. 5Ag-special antibody response and protective efficacy of Ag-GPs immunization.A Schematic of immunization schedule. Mice received three rounds of immune stimulation at weekly intervals (−21, −14, and −7 dpi). On day 7 after the last immunization, mice were orally infected with 300 ML. B, C Serum IgG and IgE levels detected by ELISA at −4, 3, 7, and 35 dpi. Data are presented as mean ± SD (n = 3), *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. D Secretory IgA (SIgA) in intestinal tissues at −4, 7, and 35 dpi. Data are presented as mean ± SD (n = 3), *P < 0.05, **P < 0.01, and ****P < 0.0001. E, F The number and reduction rate of adult worms in mice vaccinated at 7 dpi. Data represent mean ± SD (n = 12/group). ***P < 0.001, and ****P < 0.0001. G, H The LPG and reduction rate of muscle larvae in vaccinated mice at 35 dpi. Data represent mean ± SEM (n = 12/group). ***P < 0.001, and ****P < 0.0001. Ag-special antibody response and protective efficacy of Ag-GPs immunization. A Schematic of immunization schedule. Mice received three rounds of immune stimulation at weekly intervals (−21, −14, and −7 dpi). On day 7 after the last immunization, mice were orally infected with 300 ML. B, C Serum IgG and IgE levels detected by ELISA at −4, 3, 7, and 35 dpi. Data are presented as mean ± SD (n = 3), *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. D Secretory IgA (SIgA) in intestinal tissues at −4, 7, and 35 dpi. Data are presented as mean ± SD (n = 3), *P < 0.05, **P < 0.01, and ****P < 0.0001. E, F The number and reduction rate of adult worms in mice vaccinated at 7 dpi. Data represent mean ± SD (n = 12/group). ***P < 0.001, and ****P < 0.0001. G, H The LPG and reduction rate of muscle larvae in vaccinated mice at 35 dpi. Data represent mean ± SEM (n = 12/group). ***P < 0.001, and ****P < 0.0001. To assess the protective effect of Ag-GPs, we examined AD and ML burdens at 7 dpi and 35 dpi. The Ag-GPs group showed a significant reduction in both AD (47 ± 12) and LPG (1198 ± 159) compared to the PBS control (158 ± 16 for AD and 2954 ± 246 for LPG) (P < 0.0001, Fig. 5E, G), with reductions of 69.95% and 59.44%. Immunization with Ag and GPs reduced AD and ML numbers, with the Ag group showing 23.92% and 26.19% reductions (P < 0.0001, Fig. 5F, H), and the GPs group showing 30.26% and 28.13% reductions (P < 0.001, Fig. 5F, H), respectively. Ag-GPs enhance protective immunity via Dectin-1 CLSM analysis revealed that LA significantly suppressed Ag-GPs uptake by RAW264.7 and DC2.4 cells (Fig. 6A). Correspondingly, ex vivo imaging showed that LA pre-treatment group reduced fluorescence intensity in PP, MLN, and ILN compared to PBS + FITC-Ag-GPs group, while showing no significant difference from the PBS control group (Fig. 6B). The results show that Dectin-1 receptor was involved in the recognition and uptake of Ag-GPs.Fig. 6Dectin-1 receptor modulates antigen uptake and anti-Trichinella immunity.A CLSM images of RB-Ag-GPs (red) uptake in Raw264.7 and DC2.4 cells pre-treated with PBS or LA (10 μg/mL, 2 h). Nuclei counterstained with DAPI (blue). B Ex vivo fluorescence imaging of FITC-Ag-GPs distribution in LA or PBS-pretreated mice at 4 h post-administration. Tissues analyzed: ILN, PP, MLN, IE, and major organs. C Dectin-1 mRNA expression levels in intestinal tissues of immunized mice at 7 dpi. Data are presented as mean ± SD (n = 3). ns not significant, ***P < 0.01, ****P < 0.0001. D, E Larvae per gram (LPG) of muscle burden and the reduction rate in mice following T. spiralis infection with vaccination at 35 dpi. Data are presented as mean ± SD (n = 3), *P < 0.05, **P < 0.01. F–H Ag-specific serum antibody levels (IgG, IgE, SIgA) in orally immunized mice. Data are presented as mean ± SD (n = 3), *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. Dectin-1 receptor modulates antigen uptake and anti-Trichinella immunity. A CLSM images of RB-Ag-GPs (red) uptake in Raw264.7 and DC2.4 cells pre-treated with PBS or LA (10 μg/mL, 2 h). Nuclei counterstained with DAPI (blue). B Ex vivo fluorescence imaging of FITC-Ag-GPs distribution in LA or PBS-pretreated mice at 4 h post-administration. Tissues analyzed: ILN, PP, MLN, IE, and major organs. C Dectin-1 mRNA expression levels in intestinal tissues of immunized mice at 7 dpi. Data are presented as mean ± SD (n = 3). ns not significant, ***P < 0.01, ****P < 0.0001. D, E Larvae per gram (LPG) of muscle burden and the reduction rate in mice following T. spiralis infection with vaccination at 35 dpi. Data are presented as mean ± SD (n = 3), *P < 0.05, **P < 0.01. F–H Ag-specific serum antibody levels (IgG, IgE, SIgA) in orally immunized mice. Data are presented as mean ± SD (n = 3), *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. We further examined Dectin-1 expression in intestinal tissues using qPCR. GPs and Ag-GPs groups showed higher Dectin-1 mRNA levels than the PBS control (P < 0.001; Fig. 6C). However, this upregulation was markedly suppressed by LA pretreatment in the LA+Ag-GPs group (P < 0.0001; Fig. 6C), confirming that LA effectively inhibits the expression of Dectin-1 by Ag-GPs. Compared to the Ag-GPs group, the LA+Ag-GPs group exhibited a weakened Ag-GPs protective effect (P < 0.01, Fig. 6D, E) and lower levels of Ag-specific serum antibodies, including IgG, IgE, and SIgA (P < 0.05, P < 0.01, Fig. 6F–H). These findings indicate that Dectin-1 signaling is key for Ag-GPs-induced antibody production and anti-Trichinella activity. The BSA-GPs group had a significantly lower reduction T. spiralis effect than the Ag-GPs group (Fig. S4a, b), and was no different from the GPs group. This shows Ag-GPs’ protective effect depends on delivering the Ag protein, as irrelevant proteins don’t work well. Discussion Food-borne intestinal helminth infections, particularly those caused by T. spiralis, represent a substantial global health and economic burden, underscoring the urgent need for effective prophylactic strategies. T. spiralis, a typical food-borne intestinal helminth, imposes a significant global health and economic burden. An ideal vaccine should target the parasite during its intestinal larval stage, thereby preventing systemic dissemination and eliminating adult worms before the establishment of chronic intracellular parasitism23,24. The development of an effective oral vaccine necessitates a delivery system that can protect the antigen from the harsh milieu of the gastrointestinal tract and efficiently deliver it to mucosal immune inductive sites. GPs utilized in this study, characterized by a hollow, porous structure and an average diameter of approximately 3.27 ± 0.38 μm, are well-suited for this purpose. This particle size is considered optimal for uptake by M cells overlying PPs in the gut-associated lymphoid tissue (GALT), a primary inductive site for mucosal immunity25. Indeed, the present study demonstrated efficient uptake of Ag-GPs by phagocytic cells and their transport to PPs, MLNs, and ILNs. A critical attribute of these Ag-GPs is their remarkable stability in SGF and SIF, with minimal antigen leakage and structural degradation observed. This resilience is paramount for preserving antigen integrity until it reaches the GALT, a significant advantage over soluble antigens or less stable particulate systems like some liposomal or chitosan-based formulations, which can be susceptible to enzymatic and pH-mediated degradation26. While other particulate carriers such as liposomes and chitosan nanoparticles offer antigen protection and have been explored for oral vaccine delivery27, yeast-derived GPs possess an intrinsic pathogen-associated molecular pattern (PAMP) quality due to their β-(1,3)/(1,6)-glucan composition28. Beyond their role as protective antigen carriers, GPs function as potent immunoadjuvants, a dual capacity that simplifies vaccine formulation and can enhance immunogenicity. This contrasts with many synthetic carriers that may require co-formulation with distinct adjuvants to achieve comparable immunostimulatory effects29. The work by De Smet et al. supports the capacity of β-glucan microparticles for oral antigen delivery and immune activation22, aligning with the findings presented herein. This intrinsic adjuvanticity is largely attributed to innate immune cells such as DCs, which serve as key regulators of immune responses by capturing and processing antigens and influencing T cell differentiation30–32. While our in vitro data show that Ag-GPs induce the maturation of BMDCs, demonstrating intrinsic adjuvant potential, direct in vivo evidence of mucosal DC activation and subsequent T cell subset polarization directly within the inductive sites (such as Peyer’s patches) remains to be empirically established. The co-localization of the T. spiralis antigen and the β-glucan adjuvant within a single particulate entity (Ag-GPs) ensures that antigen-presenting cells (APCs) encounter both the antigen and the adjuvant simultaneously, a condition known to optimize APC activation and subsequent T cell priming, potentially leading to a more robust and targeted immune outcome than if the antigen and a soluble adjuvant were administered separately. This principle is well-established in vaccinology, where the spatial and temporal coordination of antigen and adjuvant delivery is crucial for efficacy33. Subsequently, the cellular arm of the adaptive immune response was also robustly activated by Ag-GP immunization. These cellular events are vital for sustaining long-term immunity and effective pathogen clearance30,31. This was evidenced by a significant increase in the total splenic CD3+ T cell population, a marked elevation in the proportion of CD4+ T helper cells, and consequently, a significantly higher CD4+/CD8+ T cell ratio in vaccinated mice compared to controls. CD4+ T helper cells are central orchestrators of anti-helminth immunity, providing essential help for B cell antibody production and activating various effector cells34. The observed enhancement of antigen-specific lymphocyte proliferation ex vivo further substantiates the capacity of Ag-GPs to effectively prime adaptive T cell responses. These T cell responses are consistent with the known ability of β-glucans to activate T cells, typically mediated through the initial activation of APCs like dendritic cells32. Furthermore, the observed decrease in the proportion of CD8+ T cells alongside the increase in CD4+ T cells might reflect a strategic skewing of the immune system towards Th-mediated effector functions, which are more critical for controlling large, extracellular helminths, rather than cytotoxic T lymphocyte (CTL) responses that are typically directed against intracellular pathogens35. Oral immunization with Ag-GPs elicited a multifaceted humoral immune response, which is essential for effective anti-helminth immunity and characterized by the significant induction of T. spiralis-specific serum IgG and IgE, alongside high levels of intestinal SIgA. While dissecting the precise, independent contribution of each isotype is complex, their roles are established as distinct and synergistic. Systemic IgG antibodies are crucial for combating helminth larvae that migrate through host tissues. IgE serves as a hallmark of the protective Th2-mediated response, activating effector cells such as mast cells and eosinophils to promote worm expulsion36. Concurrently, the robust mucosal SIgA provides the “first line of defense” by preventing pathogen adhesion and neutralizing parasitic products within the gut lumen37–39. While a concurrent and robust multi-isotype response was observed, our current experimental design lacks the direct functional evidence (e.g., utilizing IgA or IgE knockout murine models) needed to define the precise, independent contribution of individual local (SIgA) or systemic (IgG, IgE) antibody compartments to the observed protection against T. spiralis. This translated directly into significant reductions in both adult worm and larval burdens, surpassing previous oral vaccine formulations10,40. Foundational work by Brown and Gordon has established the importance of Dectin-1 in recognizing β-glucans and initiating mammalian immune responses41. A pivotal finding of our study involves C-type lectin receptor Dectin-1 in mediating the uptake and immunostimulatory effects of the Ag-GP vaccine. The study demonstrated that Ag-GPs were efficiently internalized by phagocytic cell lines (RAW264.7 macrophages and DC 2.4 dendritic cells), but notably not by Caco-2 intestinal epithelial cells, which typically lack high Dectin-1 expression. This selective uptake was significantly abrogated by pre-treatment with LA, a known Dectin-1 antagonist42,43. These in vitro observations were strongly corroborated by ex vivo imaging, where LA pre-administration markedly reduced the accumulation of fluorescently labeled Ag-GPs in PPs, MLNs, and ILNs of mice, confirming Dectin-1’s role in the initial capture and transport of Ag-GPs within the GALT. The significance of Dectin-1 extends far beyond mere particle uptake; it is fundamentally involved in the adjuvant activity of GPs and the subsequent generation of protective immunity. Dectin-1 receptor agonists enhance enhancing the efficacy of parenteral vaccines by inducing strong intestinal mucosal immune responses37. In our study, the levels of Dectin-1 expression and antibody titers (especially SIgA levels) were found to be correlated with the effectiveness of immunization in reducing parasite burden. The administration of LA prior to Ag-GP immunization not only blocked particle uptake but also significantly attenuated the upregulation of Dectin-1 mRNA in intestinal tissues, suppressed the development of antigen-specific IgG, IgE, and SIgA responses, and ultimately, severely compromised the vaccine’s protective efficacy against T. spiralis challenge. These results suggest that Dectin-1 acts not merely as a passive entry receptor but is strongly associated with the overall immunogenicity and protective capacity of the Ag-GP vaccine. This chain of events, from Dectin-1 mediated uptake to the triggering of adaptive immunity and protection, highlights the significant involvement of Dectin-1 in the immune cascade initiated by this novel oral vaccine. Its blockade results in a near-complete loss of vaccine efficacy, highlighting its central and indispensable role at multiple stages of immune induction. While β-glucans are well-recognized for their immunomodulatory properties, as we noted in a previous study13, a key advancement of this work is the demonstration of the GPs’ dual functionality as both an adjuvant and a delivery system. Our experimental design included the necessary controls to differentiate these effects. The Ag-GPs group (69.95% worm reduction) provided vastly superior protection compared to immunization with the antigen alone (Ag group, 23.92%) or the GP adjuvant alone (GPs group, 30.26%). This demonstrates a strong synergistic effect, rather than a simple additive one. This synergy is attributable to the GP’s function as a delivery vehicle, which protects the antigen from gastrointestinal degradation and ensures the co-localization of the antigen and the PAMP adjuvant to the same antigen-presenting cells, a process known to be critical for potent immune priming. Furthermore, our control experiment using an irrelevant protein (BSA-GPs) showed no protective effect beyond the GPs alone, and was significantly less effective than the Ag-GPs group (Fig. S4). This unequivocally demonstrates that the vaccine’s efficacy is dependent on the specific delivery of the T. spiralis antigen, and not just the non-specific adjuvant effect of the β-glucans. This integrated approach can streamline vaccine design by potentially obviating the need for co-administered adjuvants, which often present challenges related to toxicity, formulation complexity, or stability. One innovative aspect of our study is the demonstrated biocompatibility and safety profile of Ag-GPs. The GPs are derived from chemically treated yeast cell walls and recognized as safe and non-toxic by Food and Drug Administration. In our study, despite the enhanced immunogenicity, Ag-GPs did not exhibit detectable cytotoxicity or hemolytic activity in vitro and maintained normal hematological and biochemical parameters in vivo. There are also no histopathological abnormalities in major organs. This safety profile supports their potential for clinical translation, as previous attempts at oral vaccine development often encounter toxicity or tolerance issues associated with repeated mucosal administration8. The current study possesses several notable strengths. It provides a comprehensive evaluation of the Ag-GP vaccine, encompassing detailed in vitro characterization of the particles (including structure, stability, and antigen encapsulation efficiency), ex vivo cellular uptake studies, robust in vivo assessment of both humoral and cellular immunogenicity, and a clear demonstration of protective efficacy against a live parasite challenge. A significant strength is the elucidation of the Dectin-1-dependent mechanism of action through the use of a specific antagonist, which offers clear mechanistic insights into how the vaccine initiates an immune response. Furthermore, the inclusion of thorough safety and biocompatibility assessments, including hemolysis assays, in vitro cytotoxicity tests, and in vivo toxicological analyses, underscores the translational potential of this vaccine platform. The Ag-GP platform overcomes key challenges in mucosal vaccine design and offers a promising and versatile strategy for the future development of vaccines targeting not only T. spiralis but potentially a broader range of mucosal helminths. Despite these strengths, certain limitations should be acknowledged. The antigen preparation used in this study consisted of soluble antigens derived from T. spiralis Ag. While effective in inducing protection, this is a complex and undefined mixture of proteins and other molecules. Future research would benefit from the use of well-characterized, defined recombinant or synthetic antigens. This would not only allow for more precise immunological investigations and identification of key protective epitopes but also facilitate vaccine standardization and manufacturing. The longevity of the protective immune response induced by Ag-GPs also remains to be determined, as the study assessed protection up to 35 days post-infection; long-term immunity is a critical parameter for practical vaccine application. A notable limitation concerns the formulation process, which utilized yeast RNA (yRNA) to facilitate antigen complexation within the GPs. Because single-stranded RNA is a known agonist for endosomal Toll-like receptors (such as TLR7/8), yRNA may exert independent or synergistic immunostimulatory effects. Future iterations of this platform must either employ RNA-free encapsulation techniques or include rigorous RNA-only controls to delineate these pathways. Another major limitation of this study is the reliance on correlative observations rather than direct functional evidence. Because our assessments of cellular immunity were primarily based on splenocytes, we lack direct in vivo characterization of dendritic cell and T cell subset activation within local inductive sites, such as the GALT. Furthermore, without the use of specific knockout models or adoptive transfer experiments, the exact, independent mechanistic roles of specific antibody isotypes (particularly SIgA and IgE) and specific T cell subsets in mediating protection against T. spiralis remain unproven. Future investigations utilizing targeted transgenic models are essential to definitively elucidate these pathways. While we demonstrated significant systemic CD4+ T cell activation, future studies should focus on phenotyping T-cell responses directly within GALT, such as the Peyer’s patches and mesenteric lymph nodes, to further delineate the local priming mechanisms. Concurrently, a more detailed characterization of the T helper cell subsets (Th1, Th2, Th17, Treg) and their associated cytokine profiles was not performed in the present study. Such characterization is essential, as β-glucans can induce diverse immune polarizations depending on their properties and administration context, sometimes favoring Th1 or Th17 profiles. Furthermore, while we inferred an anti-helminth immune response based on CD4 + T cell expansion and IgE production, we did not directly measure the specific mucosal effector programs required for T. spiralis expulsion, such as the IL-4/IL-13 axis, mast cell degranulation, or eosinophil mobilization. The precise nature of the Th polarization and subsequent mucosal effector mechanisms induced by Ag-GPs remain to be definitively characterized in future investigations. Direct measurement of key polarizing cytokines is therefore warranted in future investigations to fully delineate the complete immune signature induced by Ag-GPs. Concurrently, while our pharmacological blockade with laminarin provided strong evidence for the role of Dectin-1, future studies using Dectin-1 knockout mice would be valuable to definitively confirm this mechanism and explore any potential, minor contributions from alternative uptake pathways. It should be also noted that our laminarin blockade experiment utilized a single-dose protocol, which may not fully recapitulate the receptor engagement dynamics of the three-dose vaccination regimen used for the efficacy studies. Finally, progression towards testing the Ag-GP platform in target animal species, such as pigs for trichinellosis control, will be vital for assessing its efficacy and safety in a setting that is more directly relevant to its intended application. In summary, the current study introduces a novel oral vaccine formulation based on GPs derived from Saccharomyces cerevisiae, encapsulating soluble antigens from T. spiralis. The principal findings demonstrate that these Ag-GPs exhibit excellent stability in simulated gastrointestinal conditions, achieve efficient antigen encapsulation, and possess a favorable biocompatibility profile. Crucially, oral immunization with Ag-GPs induced significant protective immunity against T. spiralis challenge in mice, evidenced by marked reductions in both adult worm and muscle larval burdens. A key observation from this work is the strong correlation between protective efficacy and Dectin-1 receptor-mediated cellular uptake and subsequent immune activation. This study effectively addresses two major impediments in oral vaccine development against parasitic infections: the degradation of antigens within the gastrointestinal tract and the difficulty in stimulating potent mucosal immune responses. The inherent stability of the GP carrier protects the antigenic cargo, while its particulate nature and composition facilitate targeted delivery and potent immunostimulation at mucosal inductive sites. Methods Animals BALB/c mice (female, 6 weeks old) were purchased from Changchun Yisi Experimental Animals Technology Co., Ltd and kept in a temperature-controlled room (22 ± 2°C) under a 12 h dark-light cycle. All animal experiments were conducted in accordance with the National Research Council’s Guide for the Care and Use of Laboratory. The protocol was approved by the Institutional Animal Care and Use Committee of Jilin University (Permit No. KT20230367). Preparation of Ag-GPs Muscle larvae (ML) of T. spiralis (ISS534) were isolated from experimentally infected Wistar rats at 35 days post-infection (dpi). Soluble antigens of ML were prepared using a protocol from previous studies44. Briefly, ML were homogenized in PBS containing 1 mM Phenylmethylsulfonyl fluoride (PMSF, ST505, Beyotime, China) to release soluble proteins. The homogenate was centrifuged at 8000 rpm for 10 min, and the supernatant containing Ag was collected. Protein concentration was quantified using a bicinchoninic acid (BCA, P0010S, Beyotime, China) assay kit, followed by lyophilization and storage at −20 °C. GPs were extracted from baker’s yeast (100029078706, Angelyeast, China) following the protocol established by Zeynep Mirza et al.45,46. In brief, 100 g of yeast cells were added to 1 L of 1 M NaOH, heated to 60 °C for 30 min, and subsequently maintained at 80 °C for 1 h. The insoluble fraction was washed with sterile water until the supernatant became no visible turbidity, adjusted to pH 4.5 with hydrochloric acid, and stirred at 60 °C for 1 h. Sequential washes with sterile water, isopropanol, and acetone were performed, followed by centrifugation at 8000 rpm for 5 min after each step. The final GPs solution was spray-dried using an OM-1500A spray dryer (Shanghai Ou Menu, China) to obtain 6.7 g of a grayish-white powder. Ten milligrams of GPs were swollen with 80 µL of a 25 mg/mL Ag solution at 4 °C for 2 h to facilitate Ag diffusion into the GPs cavities. Subsequently, the swollen samples were freeze-dried, rehydrated at 4 °C, and refreeze-dried to incorporate Ag into the interior. The particles were swollen with 80 µL of a 25 mg/mL Yeast RNA (yRNA, Type VI, R6625, Sigma-Aldrich, Germany) solution for 30 min at 50 °C, then with an excess of 10 mg/mL yRNA solution for another hour to complete complexation. Unencapsulated Ag was removed by triple PBS washing, and its concentration was quantified via BCA assay. Finally, Ag-GPs were sterilized with 70% ethanol for 30 min, washed, and freeze-dried. The encapsulation efficiency (EE) and loading efficiency (LE) were analyzed by the equation:\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\mathrm{EE}( \% )=100\times (\mathrm{total\; Ag}-\mathrm{unloaded}-\mathrm{Ag\; in\; supernatant}/\mathrm{total\; Ag}).$$\end{document}EE(%)=100×(total Ag-unloaded-Ag in supernatant/total Ag).\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\mathrm{LE}( \% )=100\times (\mathrm{total\; Ag}-\mathrm{unloaded}-\mathrm{Ag\; in\; supernatant}/\mathrm{total\; amount\; of\; Ag}-\mathrm{GPs}).$$\end{document}LE(%)=100×(total Ag-unloaded-Ag in supernatant/total amount of Ag-GPs). Fluorescent labeling of GPs and Ag For calcofluor white (CFW, 18909, Sigma-Aldrich, Germany) labeling, GPs were incubated with a 10% CFW solution at room temperature for 3 min to generate CFW-GPs. The process of labeling GPs or Ag with fluorescein isothiocyanate (FITC, HY-66019, MedChemExpress, USA) or rhodamine B (RB, R6626, Sigma-Aldrich, Germany) were similar47. Briefly, the dry GPs or Ag were incubated with a 2.5 mg/mL FITC or RB solution overnight in the dark, and then quenched the free dye with 1 M Tris buffer solution (PH 8.3). Labeled GPs (CFW-GPs, FITC-GPs, RB-GPs) were obtained through successive sterile washings, while labeled Ag (FITC-Ag, RB-Ag) was dialyzed to remove excess dye. Characterization of the Ag-GPs Yeast, GPs and Ag-GPs were respectively dispersed in anhydrous ethanol, dropped onto a silicon wafer and dried in a fume hood for 48 h. Surface morphology was analyzed by scanning electron microscopy (SEM; Carl Zeiss, Germany). For internal structure analysis, the samples were dispersed in ddH2O, dropped onto a copper mesh, and then dried at room temperature. The internal structure and morphology were examined using transmission electron microscopy (TEM, Tecnai Spirit Biotwin, USA). Particle size analysis via ImageJ software demonstrated uniform Ag-GPs dimensions. The diameters of the particles were measured from the TEM images using ImageJ software. Particles were dispersed in ultrapure water at a concentration of 0.1 mg/mL, and zeta potential was measured using a Zetasizer Nano ZS (Malvern Panalytical, UK). Fourier transform infrared spectrometer (FTIR, Bruker, Germany) confirmed Ag encapsulation: Ag, pure GPs, and GPs/Ag (GPs containing only Ag) were mixed with KBr and analyzed. RB-Ag-loaded CFW-GPs were visualized using a confocal laser scanning microscope (CLSM; Olympus, Japan). Stability of Ag GPs in simulated gastrointestinal environment Ag-GPs were incubated in SGF (R30388, Yuanye, China) for 2 h, then transferred to SIF (R3038, Yuanye, China) and incubated until 8 h. At 1, 2, 4, 6, and 8 h, Ag-GPs morphology was observed by CLSM, and their size was determined using ImageJ software. The number of remaining particles was measured quantified using a hemocytometer. Ag-GPs were incubated in PBS buffer (pH 1.2, 37 °C, 250 rpm for 2 h), then transferred to PBS buffer (pH 6.8) and incubated until 8 h. Ag release from Ag-GPs was conducted in an oscillator at 4 °C and 1000 rpm. Fresh media were periodically replaced until no Ag was detectable, with released Ag quantified via BCA assay. Hemolytic assay Sheep red blood cells (SRBCs, R22332, Yuanye, China) were resuspended 1:50 in Ag-GPs solution (62.5–200 µg/mL), PBS (negative control) or ddH2O (positive control), followed by 37 °C incubation for 4 h. After centrifugation at 800 rpm for 5 min, samples were aligned horizontally for photographing to observe hemolysis. The hemolysis rates were determined by measuring the absorbance of the supernatants at 542 nm. Cytotoxicity of Ag-GPs The Caco-2, Raw264.7, and DC2.4 cells were cultured in complete RPMI 1640 medium (PM150110, Procell, China) supplemented with 10% fetal bovine serum (FBS, 164210-50, Procell, China) under a 5% CO₂ atmosphere. Raw264.7, Caco-2, and DC2.4 cells were seeded in a 96-well plate and cultured for 24 h. Cells were treated with Ag-GPs (10–200 μg/mL) for 24 h. After removing the medium, 90 μL RPMI 1640 medium and 10 μL cell counting kit-8 (CCK-8, C0037, Beyotime, China) reagent were added. Cell viability was quantified by measuring absorbance at 450 nm after 4 h incubation. In vivo toxicity of Ag-GPs Mice received three oral doses of PBS, Ag, GPs, or Ag-GPs at 7-day intervals and were euthanized 14 days post-immunization by CO2 asphyxiation until cardiac arrest was confirmed. Blood was then collected by intracardiac puncture, and cervical dislocation was subsequently performed to ensure death. EDTA-anticoagulated blood was analyzed for hematological parameters (hemoglobin concentration, differential counts of lymphocytes, monocytes, red blood cell and neutrophils) using a veterinary hematology analyzer (Drew Scientific, USA). Serum liver/kidney functional markers, including albumin (ALB), alanine aminotransferase (ALT), blood urea nitrogen (BUN), and creatinine (CRE), were detected in serum using a biochemical analyzer (Sysmex Corporation, Japan). Main organs (heart, lungs, liver, spleen, kidneys) and gastrointestinal tissues (stomach, ileum, colon) were fixed in 4% paraformaldehyde for 24 h, and then embedded in paraffin for sectioning. The tissues were stained with hematoxylin and eosin (H&E) and imaged under a light microscope at ×200 magnification. Cellular uptake of Ag-GPs in phagocytic Raw264.7, DC2.4, and Caco-2 cells in 24-well plates were incubated with RB-Ag-GPs for 4 h, fixed with 4% paraformaldehyde, stained with PKH67 green fluorescent cell linker kit (PKH67GL, Sigma-Aldrich, Germany) for membrane labeling and DAPI anti-fade mounting medium (DAPI, HY-K1047, MedChemExpress, USA) for nuclear staining, followed visualized by CLSM. Transport of Ag-GPs in the gastrointestinal tract Mice were gavaged with FITC-Ag-GPs or PBS were enthanized after 4 h. ILN, PP, MLN, intestinal epithelia (IE), and major organs (heart, lungs, liver, spleen, kidneys) were collected. ex vivo imaging was analyzed using an IVIS Lumina LT imaging system (PerkinElmer, USA) to examine the distribution of fluorescence signal produced by RB-Ag-GPs. BMDCs maturation assay Bone marrow-derived dendritic cells (BMDCs) were isolated48 and cultured in DC complete medium(CM-M151A, Pricella, China) for 6 days. Subsequently, BMDCs were treated with Ag, GPs, or Ag-GPs or sterile PBS (negative control) for 24 h, then stained with PE-anti-CD11c, FITC-anti-CD86, and APC-anti-CD80 (553164, 561962, 553141, R&D Systems, USA) antibodies. Subsequently, the stained cells were analyzed by flow cytometry to evaluate the co-expression of surface markers CD80/CD86. Impact of Ag-GPs on spleen immune response Spleens were isolated from mice 3 days post-third immunization and single-cell suspensions were prepared as previously described49. Splenocytes were stained with APC-anti-CD3, FITC-anti-CD4, and PE-anti-CD8 (553066, 557307, 553032, R&D Systems, USA) antibodies. The numbers of CD3⁺, CD4⁺, and CD8⁺ T cells and the CD4⁺/CD8⁺ ratio were analyzed by flow cytometry. Additionally, purified splenocytes (1 × 10⁶ cells/well) were seeded in a 96-well plate, stimulated with Ag at 50 µg/mL for 48 h, and their proliferative response was assessed using the CCK-8 assay. Vaccination and challenge protocols To investigate the immunoprotective effect of the Ag-GPs oral vaccine, we designed a multiple immunization schedule, and the processes of vaccinations and challenge assays are recorded in Fig. 5A. Mice were randomly divided into four groups: (1) PBS control; (2) Ag (50 μg/mouse); (3) GPs (395 μg/mouse); (4) Ag-GPs (395 μg/mouse). Mice received three vaccinations at 7-day intervals and were gavaged with T. spiralis larvae 7 days after the last immunization. Detection of Ag-specific antibody levels by ELISA Mice were briefly anesthetized via intraperitoneal injection of 1.25% Avertin (LAT-AFD0306, Lab Animal Technology Develop Co, China), and blood was collected from the facial vein. The serum levels of Ag-specific IgG and IgE were quantified by ELISA50. Briefly, 96-well plates were coated with 10 µg/mL Ag at 4 °C overnight. Plates were blocked with 5% BSA for 2 h at 37 °C, washed with PBST, and incubated with diluted sera (1:30 for IgG; 1:4 for IgE) for 1 h at 37 °C. After washes, plates were incubated with HRP-conjugated anti-mouse IgG (ab6728, Abcam, UK, 1:5000) or IgE (ab99574, Abcam, UK, 1:3000) for 1 h at 37 °C, then washed again. TMB substrate was added, followed by 2 M H2SO₄ to terminate the reaction, and specific antibody levels were reported as optical density (OD) values measured at 450 nm. To detect Ag-specific SIgA (ab97235, Abcam, UK, 1;10000) in intestinal tissue, 2.5 mg tissue was homogenized in 1 mL PBS with 1% PMSF, centrifuged at 8000 rpm for 15 min at 4 °C, and the supernatant was used for SIgA quantification by ELISA. Adult worm or muscle larvae burden Mice were euthanized to collect adult worms (AD, 7 dpi) and ML (35 dpi) and to perform counting51,52. The amount of AD and muscle larvae per gram (LPG) was quantified to evaluate the protective effect of Ag-GPs on T. spiralis. Dectin-1 receptor: immune recognition and functional role To investigate the effect of Dectin-1 receptor on the uptake of Ag-GPs by phagocytic cells. RAW264.7 and DC2.4 cells were pretreated with laminarin (LA, L9634, Sigma-Aldrich, Germany, a Dectin-1 antagonists) or PBS for 2 h, then incubated with RB-Ag-GPs for 4 h. After the incubation period, the cells were fixed and stained to image their uptake of RB-Ag-GPs. In the gastrointestinal transport study, mice were pretreated orally with LA or PBS for 2 h, followed by oral administration of FITC-Ag-GPs for 4 h. Control groups included PBS+Ag-GPs (targeted uptake control) and PBS (background control). Tissues were excised for ex vivo fluorescence imaging to assess biodistribution of FITC-Ag-GPs. To investigate the impact of the Dectin-1 receptor on the subsequent immune-protective effects, mice were divided into six experimental groups (PBS, Ag, GPs, Ag-GPs, LA+Ag-GPs, BSA-GPs) and received a single oral dose 7 days pre-infection. After 7 days, Dectin-1 mRNA in small intestine was quantified by qPCR (TRIzol-extracted RNA). Subsequently, Ag-specific antibody levels in mouse serum were measured at 35 dpi. The number of ML was quantified to evaluate the protective efficacy (Scheme 1).Scheme 1The protective efficacy and mechanisms of oral Ag-GPs vaccine in trichinellosis.Left panel: After oral administration, antigen-loaded glucan particles (Ag-GPs) maintain structural integrity in the gastrointestinal tract. They are efficiently internalized by M cells in Peyer's patches via the Dectin-1 receptor, then further taken up by macrophages and transferred to gut-associated lymphoid tissue, leading to significantly elevated Ag-specific antibody levels in immunized mice, including IgA, IgG, and IgE. Right panel: Post-challenge, immunized mice showed markedly decreased adult worm burdens in the intestine and reduced larval loads in muscle tissue, demonstrating robust protective efficacy of the oral Ag-GPs vaccine. The protective efficacy and mechanisms of oral Ag-GPs vaccine in trichinellosis. Left panel: After oral administration, antigen-loaded glucan particles (Ag-GPs) maintain structural integrity in the gastrointestinal tract. They are efficiently internalized by M cells in Peyer's patches via the Dectin-1 receptor, then further taken up by macrophages and transferred to gut-associated lymphoid tissue, leading to significantly elevated Ag-specific antibody levels in immunized mice, including IgA, IgG, and IgE. Right panel: Post-challenge, immunized mice showed markedly decreased adult worm burdens in the intestine and reduced larval loads in muscle tissue, demonstrating robust protective efficacy of the oral Ag-GPs vaccine. Statistical analysis The GraphPad Prism (version 8.0) software was used for statistical analysis and graphing. All experiments were replicated at least twice, and the data presented are representative of these independent experiments. Comparisons among three or more groups were conducted using one-way or two-way ANOVA with Tukey’s adjustment for multiple comparisons. Statistical details for each experiment, including the number of samples (or animals) “n”, are stated in the Figure legends. Notably, while in vitro and cellular assays used n = 3 per group, all in vivo protective efficacy studies (worm burden, Fig. 5) utilized a robust sample size of n = 12 per group to ensure statistical power. Data are expressed as mean ± SD (or SEM, as indicated). ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Supplementary information Supplementary information supplementary files Supplementary information supplementary files